About: IgA dominates the early neutralizing antibody response to SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IgA dominates the early neutralizing antibody response to SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IgA dominates the early neutralizing antibody response to SARS-CoV-2
Creator	Charneau, Pierre Mayaux, Julien Guihot, Amélie Luyt, Charles-Edouard Anna, François Beurton, Alexandra Mathian, Alexis Miyara, Makoto Amoura, Zahir Claër, Laetitia Dorgham, Karim Fadlallah, Jehane Fourati, Salma Ghillani, Pascale Gorochov, Guy Gunn, Cary Hockett, Rick Lacorte, Jean-Marc Mohr, Audrey Mudumba, Sasi Parizot, Christophe Quentric, Paul Sterlin, Delphine Yssel, Hans
Source	MedRxiv
abstract	A major dogma in immunology has it that the IgM antibody response precedes secondary memory responses built on the production of IgG, IgA and, occasionaly, IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of specific, neutralizing, antibodies in serum and broncho-alveolar fluid of 145 patients with COVID-19. Surprisingly, early SARS-CoV-2-specific humoral responses were found to be typically dominated by antibodies of the IgA isotype. Peripheral expansion of IgA-plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. While the specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization, as compared to IgG. However, specific IgA serum levels notably decrease after one month of evolution. These results represent a challenging observation given the present uncertainty as to which kind of humoral response would optimally protect against re-infection, and whether vaccine regimens should consider boosting a potent, although, at least in blood, fading IgA response.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.1101/2020.06.10.20126532
has license	medrxiv
sha1sum (hex)	e043efe8ce170f6bb92710ccc21c1302f95d032b
schema:url	https://doi.org/10.1101/2020.06.10.20126532
resource representing a document's title	IgA dominates the early neutralizing antibody response to SARS-CoV-2
resource representing a document's body	covid:e043efe8ce170f6bb92710ccc21c1302f95d032b#body_text
is schema:about of	named entity 'neutralizing antibody' named entity 'response' named entity 'EARLY' named entity 'INCLUDED' named entity 'VIRUS NEUTRALIZATION' named entity 'IgM' named entity 'Summary' named entity 'specific' named entity 'virus' named entity 'IgA' named entity 'IgG' named entity 'virus' named entity 'SARS-CoV-2' named entity 'IgA' named entity 'response' named entity 'SENTENCE' named entity 'IgA' named entity 'IGM' named entity 'EXTENT' named entity 'IGA' named entity 'SUMMARY' named entity 'MUCH' named entity 'IGA' named entity 'antibody response' named entity 'IgM' named entity 'LARGER' named entity 'neutralizing antibody' named entity 'One' named entity 'dominates' named entity 'extent' named entity 'sentence' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'While' named entity 'IgA' named entity 'ANTIBODY RESPONSE' named entity 'SPECIFIC ANTIBODY' named entity 'IGG' named entity 'Title' named entity 'EARLY' named entity 'ANTIBODY RESPONSE' named entity 'RESPONSE TO' named entity 'SARS-COV-2' named entity 'NEUTRALIZING ANTIBODY' named entity 'TITLE'
is part of of	A major dogma in immunology has it that the IgM antibody response precedes secondary memory responses built on the production of IgG, IgA and, occasionaly, IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of specific, neutralizing, antibodies in serum and broncho-alveolar fluid of 145 patients with COVID-19. Surprisingly, early SARS-CoV-2-specific humoral responses were found to be typically dominated by antibodies of the IgA isotype. Peripheral expansion of IgA-plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. While the specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization, as compared to IgG. However, specific IgA serum levels notably decrease after one month of evolution. These results represent a challenging observation given the present uncertainty as to which kind of humoral response would optimally protect against re-infection, and whether vaccine regimens should consider boosting a potent, although, at least in blood, fading IgA response. IgA dominates the early neutralizing antibody response to SARS-CoV-2 covid:e043efe8ce170f6bb92710ccc21c1302f95d032b#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software